Design and development of multivesicular liposomal depot delivery system for controlled systemic delivery of acyclovir sodium

AAPS PharmSciTech

Volumn 6, Issue 1, 2005, Pages

  Jain, Sanjay K ^a   Jain, Rajesh K ^a   Chourasia, Manish K ^a   Jain, Akhilesh K ^a   Chalasani, Kishore B ^b   Soni, Vandana ^a   Jain, Aviral ^a  

^a Pharmaceutics Laboratory   (India)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Acyclovir sodium; Herpes simplex virus; Intradermal depot systems; Multivesicular liposomes; Sustained delivery

Indexed keywords

ACICLOVIR; CHOLESTEROL; LIPOSOME; LYSINE; PHOSPHATE BUFFERED SALINE; PHOSPHATIDYLGLYCEROL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; EVAPORATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PROCESS DEVELOPMENT; RAT; SUSTAINED RELEASE PREPARATION;

ACYCLOVIR; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; LIPOSOMES; MALE; RATS; RATS, WISTAR; TECHNOLOGY, PHARMACEUTICAL;

EID: 27744551746     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt060108     Document Type: Article

References (32)

1. Miranda PD, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. Antimicrob Chemother. 1993;12:(Suppl. B):29-37.
2. Wagstaff AJ, Faulds D, Goa KL. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;47:153-205.
3. Bryson YJ, Dillon M, Lovett M, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med. 1983;309:916-921.
4. Goldberg LH, Kaufman R, Kurtz TO, et al. Long-term suppression of recurrent genital herpes with acyclovir. Arch Dermatol. 1993;129:582-587.
5. Wade JC, Newton B, McLaren C, et al. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double blind trial. Ann Intern Med. 1982;96:265-269.
6. Ran Y, Yalkowsky SH. Halothane, a novel solvent for the preparation of liposomes containing 2-4'-amino-3'-methylphemil benzothiazole (AMPB), an anticancer drug: a technical note. AAPS PharmSciTech. 2003;4:E20.
7. Mumper RJ, Hoffman AS. The stabilization and release of hirudin from liposomes or lipid-assemblies coated with hydrophobically modified dextran. AAPS PharmSciTech. 2000; 1:E3.
8. Riaz M, Martin F, Weiner H. Liposomes as a drug delivery system. Drug Dev Ind Pharm. 1989; 15:1523-1524.
9. Lasic DD, Papadjopoulos D. Liposomes revisited. Science. 1995;267:1275-1276.
10. Meyer J, Whitcomb L, Collins D. Efficient encapsulation of proteins within liposomes for slow release in vivo. Biochim Biophys Res Commun. 1994;199:433-438.
11. Kim T, Murdane S, Gruber A, Kim S. Sustained-release morphine for epidural analgesia in rats. Anesthesiology. 1996;85:331-338.
12. Khatibi S, Howell SB, McCully C. Prolongation of action in CSF by encapsulation into multivesicular liposomes. Am Soc Clin Oncol. 1991;10:282-286.
13. Langston MV, Rampresad MP, Karali TT, Galluppi GR, Katre NV. Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam). J Control Release. 2003;89:87-99.
14. Kim S, Turker MS, Chi EY, Sela S, Martin GM. Preparation of multivesicular liposomes. Biochim Biophys Acta. 1983;728:339-348.
15. Spector MS, Zasadzinshi JA, Sankaram MB. Technology of multivesicular liposomes, a model biliquid. Foam Langmuir. 1996;12:4704-4708.
16. Katre NV, Asherman J, Schaefer H, Hora M. Multivesicular liposome (Depo Foam) technology for the sustained delivery of insulin like growth factor-I (IGF I). J Pharm Sci. 1998;87:1341-1345.
17. Kim S. Depofoam mediated drug delivery into cerebrospinal fluid. Methods Neuroscience. 1994;21:118-131.
18. Kim T, Kim J, Kim S. Extended release formulation of morphine for subcutaneous administration. Cancer Chemother Pharmacol. 1993;33:187-190.
19. Kim S, Howell S, inventors. Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride. US Patent 5 807 572. September 15, 1998.
20. Xiao CJ, Qi XR, Aini W, Wei SL. Preparation of eisplatin multivesicular liposomes and release of eisplatin from the liposomes in vitro. Yao Xue Xue Bao. 2003;38:133-137.
21. Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, Kim J. Treatment of leptomeningital metastasis with intraventricular administration of Depot cytarabine (DTC 101). Arch Neuro. 1993;50:261-264.
22. Katare NV, Asherman J, Schaeger H, Hora M. A multivesicular lipid based sustained release system for the delivery of therapeutic proteins. Proc. 8th Int. Pharm. Technol. Symp. Turkey 1996;20-21.
23. Freeman DJ, Sheth NV, Spruance SL. Failure of topical acyclovir ointment to penetrate human skin. J Antimicrob Agents Chemother. 1986;29:730-732.
24. Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci. 2000;2:E6.
25. Bundgaard H, Jensen E, Falch E. Water-soluble, solution-stable, and biolabile N-substituted (aminomethyl) benzoate ester prodrugs of acyclovir. Pharm Res. 199 1;8:1087-1093.
26. Shao Z, Park G, Krishnamoorthy R, Mitra AK. The physicochemical properties, plasma enzymatic hydrolysis, and nasal absorption of acyclovir and its 2'-ester prodrugs. Pharm Res. 1994; 11:237-242.
27. Chikhale PJ, Vcnkatraghavan V, Bodor NS. Improved delivery through biological membranes LX: Intradermal targeting of acyclovir using redox-based chemical drug delivery systems. Drug Del. 1996;3:17-26.
28. Krenitsky TA, Hall WW, de Miranda PD, Beauchamp LM Schaeffer HJ, Whiteman PD. 6-Deoxyacyclovir: a xanthine oxidaseactivated prodrug of acyclovir. Proc Natl Acad Sci USA. 1984;81:3209-3213.
29. Shojaei AH, Zhou S, Xiaoling L. Transbuccal delivery of acyclovir (II): Feasibility, system design, and in vitro permeation studies. J Pharm Pharmaceut Sci. 1998; 1:66-73.
30. Law SL, Huang KJ, Chiang CH Acyclovir-containing liposomes for potential, potential ocular delivery. Comeal penetration and absorption. J Control Release. 2000;63:135-140.
31. Seth AK, Mishra A. Mathematical modelling of preparation of acyclovir liposomes: reverse phase evaporation method. J Pharm Sci. 2002;5:285-291.
32. Boulieu R, Gallant C, Silberstein N. Determination of acyclovir in human plasma by high-performance liquid chromatography. J Chromat. 1997;B693:233-236.